BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv4.7.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.mdtechcouncil.com/membership/events
X-WR-CALDESC:Events for 
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220203T100000
DTEND;TZID=America/New_York:20220203T120000
DTSTAMP:20260415T094158
CREATED:20220119T144327Z
LAST-MODIFIED:20220119T144406Z
UID:2545-1643882400-1643889600@www.mdtechcouncil.com
SUMMARY:Gain Therapeutics R&D Day
DESCRIPTION:Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable \nAdditional details on registration\, speakers and agendas to follow and will be posted under the Events section of the Gain Website. \nAbout Gain Therapeutics\, Inc.\nGain Therapeutics\, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted\, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA\, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020\, Gain Therapeutics\, Inc. completed a share exchange with Gain Therapeutics\, SA\, a Swiss corporation\, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics\, Inc. \nFor more information\, please visit https://www.gaintherapeutics.com \n
URL:https://www.mdtechcouncil.com/membership/events/calendar/gain-therapeutics-rd-day/
END:VEVENT
END:VCALENDAR